Lineage Cell Therapeutics, Inc. (LCTX) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Lineage Cell Therapeutics, Inc., with annual and quarterly history.
| Metric | 2025 |
|---|---|
| Valuation | |
| P/E Ratio | -6.05x |
| P/B Ratio | 8.63x |
| P/S Ratio | 26.40x |
| Profitability | |
| Gross Margin | 94.2% |
| Operating Margin | -149.6% |
| Net Margin | -436.5% |
| EBITDA Margin | -144.8% |
| Liquidity | |
| Current Ratio | 5.20x |
| Quick Ratio | 5.20x |
| Leverage | |
| Debt/Equity | 0.05x |
YoY = year-over-year change. Source: FMP..